refrigeration comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-01-31. Numbers and descriptions here follow the published literature rather than marketing material.
Development began in the 2010s, when researchers modified a GIP-based scaffold to add GLP-1 activity and then attached the fatty diacid to lengthen its half-life. Clinical evaluation proceeded through large phase 3 programmes in type 2 diabetes and in obesity, and regulators in the United States cleared the compound for type 2 diabetes in 2022 and for chronic weight management in 2023. Several cardiovascular and metabolic outcome studies are still reporting, so the picture of long-term benefit and risk is incomplete. Approvals in other regions followed on different timelines.
Tirzepatide is a synthetic peptide of 39 amino acids that carries a C20 fatty diacid side chain attached through a linker. Its molecular formula is C225H348N48O68, and its molecular weight is about 4813 daltons. The compound belongs to the incretin mimetic class and is administered by subcutaneous injection. The fatty acid chain promotes binding to serum albumin, which slows renal clearance and extends the circulation time of the molecule. It was identified during screening of sequences derived from glucose-dependent insulinotropic polypeptide.
Tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor, making it a dual agonist rather than a selective agent. Engagement of the GLP-1 receptor is linked to glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. The relative contribution of the GIP arm remains an active research question; proposed roles include improved insulin sensitivity and altered adipose tissue handling. Receptor occupancy studies suggest the molecule interacts with both targets at circulating concentrations achieved during therapy.
Receptor activation by tirzepatide raises intracellular cyclic AMP through Gs-coupled signalling at both targets. At the GLP-1 receptor the downstream effect includes glucose-dependent insulin release, suppressed glucagon secretion, delayed gastric emptying, and reduced appetite signalling in the hypothalamus. GIP receptor engagement adds insulinotropic activity and appears to influence lipid handling in adipose tissue. Because both receptors are stimulated at the same time, the pharmacological profile differs from that of selective GLP-1 receptor agonists, and the relative contribution of each arm remains an area of active investigation.
Clinical development proceeded through large phase 3 programmes in type 2 diabetes and in obesity or overweight with at least one weight-related comorbidity. Regulatory approvals followed in several jurisdictions for both indications. Weekly subcutaneous dosing reflects an elimination half-life of roughly five days. Open questions include the durability of metabolic effects after treatment stops, long-term cardiovascular and hepatic outcomes beyond completed trials, and whether the dual mechanism confers benefits independent of total receptor occupancy. Published literature continues to expand on these points. Substantial uncertainty remains about interindividual variability in response.
Tirzepatide is a synthetic linear peptide of 39 amino acids that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Its sequence derives from native GIP but incorporates non-natural residues and a C20 fatty diacid moiety linked to a lysine side chain. The lipophilic chain promotes albumin binding, which slows renal clearance and extends circulation time. The unmodified peptide has a molecular formula of C225H348N48O68 and a molecular mass near 4,813 daltons.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C225H348N48O68 | Peptide backbone with a fatty diacid chain |
| Molecular weight | About 4813 Da | Calculated from the formula |
| Receptor targets | GIP and GLP-1 receptors | Dual agonist activity at both sites |
| Route of administration | Subcutaneous injection | No approved oral form at present |
| Elimination half-life | About 5 days | Supports extended intervals between administrations |
Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its sequence is related to human glucose-dependent insulinotropic polypeptide, with modifications that include a C-terminal extension and a C20 fatty diacid joined through a linker. Those changes raise the molecule's affinity for serum albumin, which slows renal filtration and lengthens the time it stays in circulation. The free base has an average molecular mass near 4813.5 daltons. The compound is made by solid-phase peptide synthesis followed by chromatographic purification.
At the receptor level, tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Both belong to the class B family of G protein-coupled receptors and signal largely through cyclic AMP accumulation. The compound binds the two receptors with differing affinity, and the pattern of signaling at each site is described in the literature as biased rather than simply proportional to occupancy. Tissues carrying these receptors include pancreatic islets, adipose tissue, the central nervous system, and the gastrointestinal tract. The relative weight of each receptor population in producing metabolic effects continues to be studied.
Tirzepatide is a synthetic peptide of 39 amino acids engineered from the native glucose-dependent insulinotropic polypeptide sequence. Its structure incorporates several non-natural residues and a C-terminal segment derived from glucagon-like peptide-1, together with a C20 fatty diacid moiety attached through a linker. The lipophilic side chain promotes binding to serum albumin, which slows renal clearance after administration. The compound is classified as a dual incretin receptor agonist and is supplied as a lyophilized powder for reconstitution or as a preformulated solution, depending on the presentation.
The peptide activates two G protein-coupled receptors, GIPR and GLP-1R. Binding triggers adenylyl cyclase activity and raises intracellular cyclic AMP in pancreatic beta cells, which potentiates insulin release when glucose is elevated. Signaling in the central nervous system is associated with reduced appetite and lower energy intake, while effects on gastric emptying and glucagon secretion are also reported. Because activity at both receptors is retained, the pharmacological profile is often described as incretin-based rather than selective for a single receptor.
After subcutaneous injection, absorption is gradual, and peak plasma levels are generally reached within one to three days. Albumin binding extends the apparent half-life to roughly five days, which supports a weekly administration schedule. Metabolism proceeds mainly through proteolytic cleavage of the peptide backbone and beta-oxidation of the fatty acid chain, rather than through cytochrome P450 pathways. Eliminated fragments are largely recycled through general protein turnover, and excretion of intact drug in urine is minimal. These properties distinguish the molecule from short-acting incretin mimetics.
Analytical characterization of tirzepatide typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) for purity assessment and peptide mapping. Mass spectrometry, often coupled with electrospray ionization, confirms molecular weight and sequence integrity. Amino acid analysis and capillary electrophoresis may also be used to detect impurities or degradation products. These methods are essential for batch release and stability studies.
Storage recommendations for tirzepatide generally specify refrigeration at 2–8 °C to maintain stability. The peptide should be protected from light and kept in its original packaging to prevent aggregation or adsorption. Freezing is not recommended because freeze-thaw cycles can cause aggregation or precipitation. Once dispensed, storage conditions and in-use periods follow product-specific labeling, which may allow room temperature storage for a limited time.
Long-term storage of the solid generally relies on temperatures at or below minus twenty degrees Celsius, while short-term working stocks may be held refrigerated. Light exposure is limited because photodegradation can alter side chains over extended periods. Solutions prepared for analysis are less stable than the dry powder and are typically used within the same working day. Buffer choice matters, since some aqueous conditions favor deamidation or oxidation at specific residues. Stability data are usually generated under defined accelerated conditions and then extrapolated with stated assumptions.
Identity and purity are established with reversed-phase high-performance liquid chromatography, often paired with mass spectrometry for confirmation of the expected mass. Peptide mapping after enzymatic digestion verifies the primary sequence and detects substitutions. Size-exclusion chromatography quantifies aggregates and fragments, which are the impurities most often tracked for peptides of this size. Residual solvents, counterions, and water content fall under separate tests described in pharmacopeial chapters. Circular dichroism or nuclear magnetic resonance may be used in research settings to probe secondary structure, though such methods are less common in routine release testing.
Ba(Cl2C=C(Cl)COO)2 → BaCl2 + ClC≡CCl + 2CO2 Dichloroacetylene was discovered as an intermediate in the synthesis of diphenylacetylene with calcium carbide, chlorine and benzene in 1918. It was first synthesized from trichloroethylene by Erwin Ott, W. Ottemeyer and K. Packendorff in 1930.
According to The Economist, "All this makes the most sense if the principal intent is to rattle Mr Maduro, give succour to Venezuela's opposition or even stir an uprising within the Venezuelan armed forces—encouraged perhaps by that recently doubled reward." Experts speaking to Reuters and the BBC described the deployment as gunboat diplomacy and Trump administration sources stated a likely goal was to pressure the Maduro administration. James G. Stavridis, a former US Navy admiral, characterized the strike and other US military activity around the same time as gunboat diplomacy intended to demonstrate the vulnerability of Venezuelan oil rigs and materiel. He wrote that drug interdiction was likely not the sole reason for the increased US military activity. The New York Times reported that a group of officials, led by US National Security Advisor and Secretary of State Marco Rubio, was pushing for a military campaign that would drive Maduro from power. Members of Venezuela's opposition told the New York Times they have coordinated with the Trump administration on a plan for the first hundred hours after Maduro's deposition. PBS News reported that Trump was using the military to counter cartels he blamed for trafficking fentanyl and other illicit drugs into the US and for fuelling violence in American cities, stating that the government had "not signaled any planned land incursion"—similarly, The Guardian stated that "many experts are skeptical the US is planning a military intervention" in Venezuela.
=== Accelerator mass spectrometry === HVEC tandems enabled accelerator mass spectrometry (AMS), a technique that transformed radiocarbon dating and created new applications across multiple fields. In May 1977, researchers at the University of Rochester used an HVEC MP tandem to demonstrate that carbon-14 atoms could be detected directly in milligram-scale samples—compared to the 10–100 grams required by conventional decay counting. The tandem configuration exploited a key property: nitrogen-14, the primary interference in conventional dating, forms no stable negative ions and cannot survive acceleration through the system, eliminating a major source of contamination. The reduction in sample size made radiocarbon dating applicable to precious artifacts and specimens where destructive sampling had been prohibitive. Tandem machines also extended the practical range of radiocarbon dating from approximately 40,000 to potentially 100,000 years. Beyond radiocarbon applications, AMS expanded into hydrology, geoscience, biomedicine, archaeology, and paleoclimatology.
== Governance == The South African Government department most related to the country's logistics sector is the Department of Transport (DoT). In 2023, the DoT released a Roadmap for the Freight Logistics System in South Africa. In the document, the government outlined that while it believed that strategic infrastructure such as rail and ports would remain publicly-owned, as it belongs to the people of South Africa, operating of such infrastructure could be opened up to private investment. Doing so, the government believes, will allow for increased efficiencies and competitiveness. The roadmap serves as a guide for state-owned transit company Transnet to achieve this balance, translating policy commitments into actions that are to be taken by the entity. In 2025, one of the themes of the Department of Transport's budget was facilitating the development of the country's air cargo capacity. Part of a R21.7-billion Airports Company South Africa (ACSA) infrastructure development allocation was set aside for increasing air freight handling through its network of airports. South Africa's fuel pipelines are regulated by the National Energy Regulator of South Africa (NERSA).
Sources: en.wikipedia.org
== Treatment == The current simplest treatment for elevated Lp(a) is to take 1–3 grams of niacin daily, typically in an extended-release form. Niacin therapy may reduce Lp(a) levels by 20–30%. However more recent research suggests that the inflammatory effects of the breakdown products of excess niacin lead to an increase in risk of major adverse cardiovascular event. A meta-analysis suggested that atorvastatin may lower Lp(a) levels. In severe cases, such as familial hypercholesterolemia or treatment-resistant hypercholesterolemia, LDL apheresis may dramatically reduce Lp(a). The goal of the treatment is to reduce levels to below 50 mg/dL. Cost is prohibitively high. PCSK9 inhibitors lower Lp(a). In the CORALreef Lipids trial, enlicitide reduced Lp(a) by 28%. Four medications are in clinical trials to lower Lp(a), including pelacarsen (80% reduction), olpasiran (95% reduction), lepodisiran (94% reduction), and muvalapin (47-86% reduction). A meta-analysis of six clinical trials confirmed that flaxseed supplementation modestly lowers Lp(a) levels. Testosterone is known to reduce Lp(a) levels. Testosterone replacement therapy also appears to be associated with lower Lp(a) levels. Estrogen replacement therapy in post-menopausal women will reduce Lp(a). Raloxifene has not been shown to reduce Lp(a), while tamoxifen has. L-carnitine may also reduce Lp(a) levels. A systematic review and meta-analysis found a significant reduction with oral but not intravenous carnitine.
Alkaloids are bitter-tasting chemicals, widespread in nature, and often toxic. There are several classes with different modes of action as drugs, both recreational and pharmaceutical. Medicines of different classes include atropine, scopolamine, and hyoscyamine (all from nightshade), the traditional medicine berberine (from plants such as Berberis and Mahonia), caffeine (Coffea), cocaine (Coca), ephedrine (Ephedra), morphine (opium poppy), nicotine (tobacco), reserpine (Rauvolfia serpentina), quinidine and quinine (Cinchona), vincamine (Vinca minor), and vincristine (Catharanthus roseus).
Phencyclidine or phenylcyclohexyl piperidine (PCP), also known in its use as a street drug as angel dust among other names, is a dissociative anesthetic mainly used recreationally for its significant mind-altering effects. PCP may cause hallucinations, distorted perceptions of sounds, and psychotic behavior. As a recreational drug, it is typically smoked, but may be taken by mouth, snorted, or injected. It may also be mixed with cannabis or tobacco. Adverse effects may include paranoia, addiction, and an increased risk of suicide, as well as seizures and coma in cases of overdose. Flashbacks may occur despite stopping usage. Chemically, PCP is a member of the arylcyclohexylamine class. PCP works primarily as an NMDA receptor antagonist. PCP is most commonly used in the US. While usage peaked in the US in the 1970s, between 2005 and 2011, an increase in visits to emergency departments as a result of the drug occurred. As of 2022, in the US, about 0.7% of 12th-grade students reported using PCP in the prior year, while 1.7% of people in the US over age 25 reported using it at some point in their lives.
Sources: en.wikipedia.org
Foreign visitors whose fingerprints are registered on arrival may use the eIACS lanes for exit clearance. In addition, the Biometric Identification of Motorbikers (BIKES) System is available for eligible motorcyclists at the land border crossings with Malaysia. Meanwhile, all visitors who have been fingerprinted on entry at a manned counter can use the eIACS to leave Singapore by air. Additionally, nationals of certain countries may register to use the eIACS system on entry, provided they meet prescribed conditions. South Korea: South Korea maintains a programme known as the Smart Entry Service, open for registration by South Koreans aged 7 or above and by registered foreigners aged 17 or above. Furthermore, visitors aged 17 or older may use the Smart Entry Service on exit at international airports, as long as they have provided their biometrics on arrival. Taiwan: An automated entry system, eGate, exists in areas administered by the Republic of China, providing expedited border control for ROC nationals as well as certain classes of residents and frequent visitors. Users scan their travel documents at the gate and are passed through for facial recognition. As of 2019, there have been instances of foreign non-registered travellers allowed to use the e-Gate system to depart, notably at Taipei Taoyuan Airport Terminal 1, but not Terminal 2, using a passport scan and fingerprints. Thailand: The automated passport control (APC) system, which uses a facial recognition system, has been available for Thai nationals since 2012, and more than 20 million have used it.
==== Spirituality ==== While religion is often formalised and community-oriented, spirituality tends to be individually based and not as formalised. In a 2014 study, 320 children, ages 8–12, in both public and private schools, were given a Spiritual Well-Being Questionnaire assessing the correlation between spirituality and happiness. Spirituality – and not religious practices (praying, attending church services) – correlated positively with the child's happiness; the more spiritual the child was, the happier the child was. Spirituality accounted for about 3–26% of the variance in happiness. Meditation has been found to lead to high activity in the brain's left prefrontal cortex, which in turn has been found to correlate with happiness. A study using the Oxford happiness questionnaire on Brahma Kumaris Raja yoga meditators showed them having higher happiness than the control group. Yongey Mingyur Rinpoche has said that neuro scientists have found that with meditation, an individual's happiness baseline can change. Many people describe themselves as both religious and spiritual, but spirituality represents just one particular function of religion. Spirituality as related to positive psychology can be defined as "a search for the sacred". What is defined as sacred can be related to God, life itself, or almost any other facet of existence. It is viewed as having spiritual implications which are transcendent of the individual. Spiritual well-being addresses this human need for transcendence and involves social as well as existential well-being.
== Personal life == McAlpine was involved in church activities. She served as President of the Manitoba Opera Guild from 1976 to 1978. She died from breast cancer in Winnipeg on 1 October 1998. Her grave is in Kilmartin Cemetery, Middlesex County, Ontario. She left a personal bequest to the University of Manitoba Department of Biochemistry and Medical Genetics to create a graduate fellowship in her name supporting students researching medical genetics.
Sources: en.wikipedia.org
It is a synthetic 39-amino-acid peptide that acts on two incretin receptors, the GIP receptor and the GLP-1 receptor. It is given by subcutaneous injection and has a circulating half-life of roughly five days. It is not a small molecule and is not absorbed usefully from the gut in conventional oral form.
Selective agents act on one receptor, while tirzepatide engages both GIP and GLP-1 receptors. The added GIP activity may contribute effects on insulin sensitivity and on fat metabolism. Whether the dual action produces meaningful clinical advantages beyond differences in potency is still being examined.
The downstream consequences of GIP receptor activation are not fully characterised in humans. It is also unclear how much each receptor contributes to appetite reduction and to shifts in body composition. Published work describes associations and proposed pathways rather than settled causal chains.
It is a dual GIP and GLP-1 receptor agonist, frequently grouped with incretin-based peptide therapeutics. It is a peptide rather than a small molecule and is given by subcutaneous injection.